Description
Breast Imaging Market—Forecast till 2027
Breast imaging Market Forecast
The breast imaging market is exceeded cross USD 6,810.80 million by 2027 to register a healthy CAGR of 8.38%. Breast imaging is a sub-strength of analytic radiology that includes imaging the breasts for screening or demonstrative purposes.
The development of the worldwide breast imaging market is driven by the elements like the rising predominance of breast disease, expanding commonness of the early location of tumors. Furthermore, the developing market for breast imaging sets out rewarding freedom for the market. Nonetheless, the related danger from radiation openness is probably going to limit the market development.
Breast imaging is a sub-division to the fame of symptomatic radiology that includes imaging the bosoms for screening or analytic purposes. The development of the worldwide breast imaging market is driven by the variables like the rising commonness of bosom malignancy, expanding pervasiveness of early location of diseases.
Additionally, the developing business sector for breast imaging sets out rewarding freedom for the market. Besides, the related danger from radiation exposure is probably going to limit the market development.
Segment Overview
The global Breast imaging market has been classified into technology and end-user.
In terms of technology type, the global market has been classified into ionizing technology, non-ionizing technology, and others. The Ionizing technology segment is further classified into Mammography, molecular breast imaging (MBI) or Molecular breast-specific Gamma Imaging (BSGI), PET-CT, Contrast-Enhanced Spectral Mammography (CESM), and Cone-Beam Computed Tomography.
The Non-Ionizing Technology segment is further classified into Breast ultrasound, Breast MRI, Breast Thermography, Optical Imaging, Microwave Imaging, Electrical Impedance Imaging (EII), and Others. Based on the end-use segment the global breast imaging market has been divided into Hospitals and clinics, specialty centers, and others.
Regional market
North America ruled the worldwide breast malignancy imaging market inferable from different factors like the high pervasiveness of breast disease among ladies, rising mindfulness about breast disease, innovative progressions, and the presence of significant makers in the area. Breast malignancy patients are expanding in the US and Canada.
It is the most normal malignancy found in American ladies, and the normal danger of creating breast disease in ladies in the US is around 13% in their life.
As indicated by the American Cancer Society, it is assessed that for breast disease in the United States in 2021, around 281,550 new instances of obtrusive breast malignancy will be analyzed in ladies, around 49,290 new instances of ductal carcinoma in situ (DCIS) will be analyzed, and around 43,600 ladies will pass on from breast disease. As indicated by the Canadian Cancer Society, in 2019, breast malignancy was the subsequent driving reason for death from disease in Canadian ladies.
Europe likewise has developed as an unmistakable market for breast imaging with an expanding commonness of breast cancer and grounded medical services foundation.
Key Competitors
The major players operating in the global Breast imaging market are Koninklijke Philips NV (Netherlands), General Electric Company (US), Siemens (Germany), Fujifilm Holdings Corporation (Japan), Hologic, Inc. (US), Delphinus Medical Technologies, Inc. (US), SonoCiné (US), CMR , aviscan Corporation (US), Planmed Oy (Finland), and KUB Technologies (US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.
Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.